Show simple item record

Dynamics of Bromodeoxyuridine Incorporation into DNA of Squamous Carcinoma Cells During Mid and Late Logarithmic Growth

dc.contributor.authorMaybaum, Jonathanen_US
dc.contributor.authorWagner, John G.en_US
dc.contributor.authorEnsminger, William D.en_US
dc.contributor.authorCarey, Thomas E.en_US
dc.contributor.authorShapira, Amnonen_US
dc.date.accessioned2006-09-08T19:21:12Z
dc.date.available2006-09-08T19:21:12Z
dc.date.issued1988-08en_US
dc.identifier.citationShapira, Amnon; Wagner, John G. ***MISSING END TAG*** Ira S.; Maybaum, Jonathan Phillip L.; Ensminger, William D.; Carey, Thomas E.; (1988). "Dynamics of Bromodeoxyuridine Incorporation into DNA of Squamous Carcinoma Cells During Mid and Late Logarithmic Growth." Pharmaceutical Research 5(8): 518-522. <http://hdl.handle.net/2027.42/41525>en_US
dc.identifier.issn0724-8741en_US
dc.identifier.issn1573-904Xen_US
dc.identifier.urihttps://hdl.handle.net/2027.42/41525
dc.identifier.urihttp://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=3244661&dopt=citationen_US
dc.description.abstractHead and neck squamous carcinoma cell lines, UM-SCC 1, 5, 9, 11B, and 14B, were exposed in vitro to bromodeoxyuridine (BUdR) during logarithmic growth to determine the effects of drug concentration (0.01 to 10 µ M ) and duration of exposure (3, 7, and 10 days) on cell growth and on incorporation of BUdR into DNA. Concentrations of less than 1.0 µ M were not growth inhibitory except with UM-SCC-11B. After 10 days of exposure to 5 µ M BUdR, survival fractions for all lines ranged from 2 to 65% of controls. Replacement of thymidine by BUdR in DNA was assessed by gas chromatography/mass spectroscopy. Percentage replacement (% R) was described by the equation % R = 100 ( C/t ) s /[( C/t ) 50 s + ( C/t ) s ], where C is the concentration of BUdR (µ M) , t is the time in days, s is a constant, and ( C/t ) 50 is a constant corresponding to % R = 50%. BUdR incorporation reached a time-and concentration-dependent maximum that, after 3 to 7 days of culture in 10 µ M BUdR, ranged from 30 to 60% R. Subsequently, % R declined with time even though the cells were fed daily with fresh BUdR-containing medium.en_US
dc.format.extent626201 bytes
dc.format.extent3115 bytes
dc.format.mimetypeapplication/pdf
dc.format.mimetypetext/plain
dc.language.isoen_US
dc.publisherKluwer Academic Publishers-Plenum Publishers; Plenum Publishing Corporation ; Springer Science+Business Mediaen_US
dc.subject.otherMedical Lawen_US
dc.subject.otherPharmacyen_US
dc.subject.otherBromodeoxyuridine (BUdR) Incorporation in Vitroen_US
dc.subject.otherPharmacology/Toxicologyen_US
dc.subject.otherBiomedicineen_US
dc.subject.otherBiochemistry, Generalen_US
dc.subject.otherSquamous Carcinoma Cellsen_US
dc.subject.otherBiomedical Engineeringen_US
dc.subject.otherThymidine Replacementen_US
dc.subject.otherKinetics of Replacementen_US
dc.titleDynamics of Bromodeoxyuridine Incorporation into DNA of Squamous Carcinoma Cells During Mid and Late Logarithmic Growthen_US
dc.typeArticleen_US
dc.subject.hlbsecondlevelPharmacy and Pharmacologyen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumDepartment of Pharmacology, The University of Michigan Medical School, Ann Arbor, Michigan, 48109; College of Pharmacy, The University of Michigan Medical School, Ann Arbor, Michigan, 48109; Upjohn Center for Clinical Pharmacology, The University of Michigan Medical School, Ann Arbor, Michigan, 48109; Department of Internal Medicine, The University of Michigan Medical School, Ann Arbor, Michigan, 48109en_US
dc.contributor.affiliationumThe University of Michigan Medical School, Ann Arbor, Michigan, 48109; Cancer Research Laboratory, 6020 KHRI, The University of Michigan, Box 0506, 1301 East Ann Street, Ann Arbor, Michigan, 48109-0506en_US
dc.contributor.affiliationumThe University of Michigan Medical School, Ann Arbor, Michigan, 48109; Department of Otolaryngology, Barzilai Medical Center, Ashkelov, 73606, Israelen_US
dc.contributor.affiliationumDepartment of Pharmacology, The University of Michigan Medical School, Ann Arbor, Michigan, 48109; Upjohn Center for Clinical Pharmacology, The University of Michigan Medical School, Ann Arbor, Michigan, 48109; Department of Internal Medicine, The University of Michigan Medical School, Ann Arbor, Michigan, 48109en_US
dc.contributor.affiliationumDepartment of Pharmacology, The University of Michigan Medical School, Ann Arbor, Michigan, 48109; Upjohn Center for Clinical Pharmacology, The University of Michigan Medical School, Ann Arbor, Michigan, 48109en_US
dc.contributor.affiliationumcampusAnn Arboren_US
dc.identifier.pmid3244661en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/41525/1/11095_2004_Article_306239.pdfen_US
dc.identifier.doihttp://dx.doi.org/10.1023/A:1015925509778en_US
dc.identifier.sourcePharmaceutical Researchen_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.